Answers to all questions asked during the webinar session and in the two Telegram channels have now been provided by the session presenters. The full Q&A has been consolidated into a single document that can be found here:

https://www.technet-21.org/en/library/main/7075-q&a-for-session-#09:-vaccination-strategies-for-covid-19-vaccination

These are the questions that have been answered:

• What are you planning to do to improve the capacity of health facilities in the face of the challenges indicated in your presentation (Uganda)?
• According to the presentation about Uganda, HIV as a comorbidity doesn't increase the risk of severe form of COVID-19. Is it true regardless of the CD4 level?
• Why is it that people with asthma and HIV are less at risk to die from COVID-19, despite these conditions having more impact on the respiratory system than diabetes or hypertension?
• I wonder if it is advisable to follow up the children of mothers vaccinated during pregnancy because the data presented refer to the time of delivery.
• How to identify and mobilize these target population for vaccination? Especially with comorbidities and elderly, particularly in the Low and Middle Income Countries with fragile health systems?